ClinicalTrials.gg
CompletedNCT05123027PILOTUpdated Feb 7, 2025Results posted

Peer Intervention to Link Overdose Survivors to Treatment (PILOT)

An interventional study of Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer and Treatment As Usual Peer in Opioid Overdose, sponsored by Medical University of South Carolina. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the Peer Intervention to Link Overdose Survivors to Treatment (PILOT) study is to improve outcomes for individuals after surviving an overdose involving opioids. This study will be comparing the enhanced peer intervention known as PILOT for overdose survivors with treatment as usual (TAU) provided in the Emergency Department.

02

Conditions studied

  • Opioid Overdose

Keywords

  • overdose
  • peer support
03

In context

Opiate Overdose

70 studies on the registry are indexed under Opiate Overdose; 11 are open to participants now.

This study's enrollment of 150 is below the median of 184 across 48 interventional studies indexed under Opiate Overdose.

Browse Opiate Overdose studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 166 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be included in this study participants must:

  1. Be 18 years of age or older at time of first contact by research staff (no upper age limit for inclusion).
  2. Meet one of the following non-fatal overdose involving opioids (NFOO) criteria:

    1. Having presented to the Emergency Department for any health issue within the past 48 hours AND self-report having a known or suspected overdose involving opioids in the past 72 hours, OR
    2. Having presented to the Emergency Department within the past 48 hours for any SUD-related health issue, self-report having a known or suspected overdose involving opioids in the past 30 days
  3. Be able to provide sufficient locator information, defined as identifying at least two individual contacts other than the participant.
  4. Be able to speak English sufficiently to understand the study procedures and provide written to participate in the study as determined by research staff.
  5. Be willing and able to confirm future SUD treatment receipt as evidenced by 2 out of 3 of the following: (a) signing appropriate releases to for study staff to confirm treatment with follow-up provider; (b) having technology necessary to visualize medication bottles and transmit to study team utilizing HIPAA-compliant platform; and/or (c) able and willing to undergo toxicology tests (in person or via HIPAA-compliant videoconferencing).

Exclusion criteria include those who are:

  1. Identified as having had an intentional overdose as the Index NFOO.
  2. Actively suicidal at the time of screening (defined as current intention and/or plan for suicide attempt).
  3. Unable to complete study baseline procedures due to medical or psychiatric condition.
  4. Currently in jail, prison or in police custody at the time of the index ED visit or under current terms of civil commitment or guardianship (i.e., OHRP-defined prisoner status).
  5. Previously randomized as a participant in this study - individuals may only be enrolled and randomized once.
  6. Unwilling to follow study procedures (e.g., unable to provide sufficient locator information [defined as two contacts] or unavailable for follow-up assessments).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer

    Behavioral: Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer · Behavioral: Treatment As Usual Peer

  • Active comparator
    Treatment As Usual Peer

    Behavioral: Treatment As Usual Peer

Interventions

  • BehavioralPeer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer

    Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.

  • BehavioralTreatment As Usual Peer

    Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.

06

What researchers measure

Primary outcomes

  1. Number of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission

    Past month total score on the modified Overdose Risk Behavior Checklist (OBRC) at 180 days (6 months post-randomization) compared between experimental groups. The ORBC was a 13-item scale with 11 of the items used to generate a total score (ranging from 0-44); higher scores indicate greater frequency and number of overdose risk behaviors.

    Time frame: 180 days (6 months)

Secondary outcomes

  1. Number of Steps Achieved Along a Modified SUD Cascade of Care

    Number of steps achieved along a modified substance use disorder (SUD) Cascade of Care (0-11 steps possible) at 180 days post-randomization (6 months). Higher scores are associated with better outcomes.

    Time frame: 180 days (6 months)

07

Results

Posted Feb 7, 2025

Participant flow

A randomized, controlled, parallel group design was implemented across three sites within the National Drug Abuse Treatment Clinical Trials Network (CTN): Prisma Health Systems (Southern Consortium Node); Mercy Health (Ohio Valley Node), and Providence Regional Medical Center (Pacific Northwest Node). From December 2021 through February 2024, 150 participants identified in the ED as opioid overdose survivors were approached to participate in the study.

Participant flow — Overall Study
MilestonePeer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual Peer
Started7278
Completed4850
Not completed2428
Withdrew: Lost to follow-up1722
Withdrew: Incarceration34
Withdrew: Death22
Withdrew: Other20

Outcome measures

PrimaryNumber of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission

Past month total score on the modified Overdose Risk Behavior Checklist (OBRC) at 180 days (6 months post-randomization) compared between experimental groups. The ORBC was a 13-item scale with 11 of the items used to generate a total score (ranging from 0-44); higher scores indicate greater frequency and number of overdose risk behaviors.

Time frame:
180 days (6 months)
Reported as:
Mean · units on a scale
Number of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission
units on a scalePILOT Intervention ArmTreatment as Usual (TAU) Arm
Number of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission4.5 ± 6.75.6 ± 7.8
Statistical analysis
  • Treatment as Usual (TAU) Arm · Mixed Models Analysis · p = 0.399 (Threshold for significance: p\< 0.05) · Risk ratio (rr): 0.70 · 95% CI 0.30 to 1.62
SecondaryNumber of Steps Achieved Along a Modified SUD Cascade of Care

Number of steps achieved along a modified substance use disorder (SUD) Cascade of Care (0-11 steps possible) at 180 days post-randomization (6 months). Higher scores are associated with better outcomes.

Time frame:
180 days (6 months)
Reported as:
Mean · units on a scale
Number of Steps Achieved Along a Modified SUD Cascade of Care
units on a scalePILOT Intervention ArmTreatment as Usual (TAU) Arm
Number of Steps Achieved Along a Modified SUD Cascade of Care4.4 ± 2.63.9 ± 2.5
Statistical analysis
  • Treatment as Usual (TAU) Arm · Mixed Models Analysis · p = 0.53 (Threshold for significance: p\< 0.05) · Risk ratio (rr): 1.09 · 95% CI 0.83 to 1.45

Adverse events

Collected over 28 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer2/72 (2.8%)21/72 (29.2%)0/72 (0%)
Treatment As Usual Peer2/78 (2.6%)18/78 (23.1%)0/78 (0%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPeer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual Peer
DeathInjury, poisoning and procedural complications1/720/78
DeathGeneral disorders1/720/78
HospitalizationSurgical and medical procedures1/720/78
HospitalizationInfections and infestations1/720/78
HospitalizationPregnancy, puerperium and perinatal conditions1/720/78
HospitalizationInjury, poisoning and procedural complications1/720/78
HospitalizationRespiratory, thoracic and mediastinal disorders1/720/78
HospitalizationPsychiatric disorders1/720/78
HospitalizationInjury, poisoning and procedural complications1/720/78
HospitalizationPsychiatric disorders1/720/78

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Peer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual PeerTotal
<=18 years000
Between 18 and 65 years7076146
>=65 years224
Age, Continuous
Age, Continuous(years)Peer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual PeerTotal
Mean39.3 ± 11.5838.1 ± 11.2838.7 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)Peer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual PeerTotal
Female213051
Male514899
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Peer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual PeerTotal
Hispanic or Latino6814
Not Hispanic or Latino6670136
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Peer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual PeerTotal
American Indian or Alaska Native325
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American111223
White5153104
More than one race268
Unknown or Not Reported5510
Baseline ORBC score
Baseline ORBC score(units on a scale)Peer Intervention to Link Overdose Survivors to Treatment (PILOT) PeerTreatment As Usual PeerTotal
Mean12.6 ± 7.412 ± 7.912.3 ± 7.7
08

Study locations

3 sites
  • Mercy Health Youngstown
    Youngstown, Ohio 44501, United States
  • Prisma Health Upstate
    Greenville, South Carolina 29605, United States
  • Providence Regional Medical Center
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Feb 2024, 25 months.

Results were first posted in Feb 2025, 11 months after primary completion.

Of 28 interventional studies with no phase under Opiate Overdose, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 17, 2021
StartActual
Dec 28, 2021
Primary completionActual
Feb 8, 2024
CompletionActual
Feb 8, 2024
Results first posted
Feb 7, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05123027
Collaborators
National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, National Institute on Drug Abuse (NIDA)
Responsible party
Kelly Barth (Professor, Medical University of South Carolina) — Principal investigator
First posted
Nov 17, 2021
Start date
Dec 28, 2021
Primary completion
Feb 8, 2024
Completion
Feb 8, 2024
Results posted
Feb 7, 2025
Last update
Feb 7, 2025

Study contacts

Kelly Barth, DO
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion